Ann: Sigma Aldrich sign license agreement for IgY, page-3

re: Ann: Sigma Aldrich sign license agreement... Even more interesting, in the Annual report they stated that, following the successful defence of the claim, the company was "now in negotiation with a number of parties to license the core parent technology that is the subject of the patents."

So a bit of a bidding war, perhaps? Certainly Sigma were sufficiently motivated to secure the technology that they firstly contested the IP in court, and when that failed they competed for it against the other interested parties and won.

Bodes well for the rest of the IP. As Nick said, "we are now in a great position to realise the full potential of HTX assets."

He also stated in the recent update that they were in "late-stage negotiations with potential US partner/s to license the Ovplex technology for distribution into the USA. With a potential market of 8 million tests at AUDS45 per unit royalty receipts, for total of AUD$336 million," the best is yet to come.

While everything biotech takes longer than expected, "Late-stage negotiations" suggests this key milestone could come sooner rather than later.